ENTELOS, Inc. Option Grants

    


Entelos Inc.



ENTELOS, Inc.

("Entelos" or "the Company")

Option Grants

Entelos, Inc. announces that it has today granted options over 248,000 new
common shares in the capital of the Company. These options have been granted to
staff under the 2006 Stock Plan and vest over a period of four years. The
exercise price of these options will be the mid-market closing price of a common
share on 28 May 2008.

Enquiries:

Entelos, Inc.
Jill Fujisaki, VP Investor Relations              Tel: +1 650 572 5400
KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
Capel Irwin/David Anderson                    Tel +44 (0) 20 4718 8900
Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson             Tel +44 (0) 20 7466 5000

Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines and
health-care related consumer products are discovered, developed, and utilized.
The Company leverages its proprietary in silico disease models, "virtual
populations", and toxicology reference systems to develop safer and more
effective drugs for pharmaceutical R&D and to help improve the quality of
health-care related consumer products. Entelos provides customized technology
and research services to global pharmaceutical, health-care, and consumer
products companies in arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization,
and personal care products. The Company is also developing a model in oncology
and is collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.

Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024